Researchers are particularly encouraged by new data involving a personalized mRNA therapy developed by Moderna and Merck.
The content creator, 41, was first diagnosed with stage 1 breast cancer in 2023. Two years later, she learned the illness ...
As we observe National Cancer Survivors Month, we delve into an exciting new era in the battle against cancer recurrence: the ...
The FDA has approved belzutifan (Welireg, Merck) in combination with pembrolizumab (Keytruda, Merck) or the subcutaneous ...
Global pharmaceutical companies Moderna and MSD announced on the 1st (local time) the results of a joint Phase 2 clinical ...
Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with ...
The authors underscored the potential of adjuvant pelvic IMRT (post-surgery pelvic radiation therapy) to enhance locoregional ...
An implanted radiation device has improved tumor control and overall survival compared with standard radiation therapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results